A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

被引：0

作者：

Mulligan, Stephen P. ^{[1
,2
,3
]}

Gill, Devinder ^{[4
]}

Turner, Paul ^{[5
]}

Renwick, William E. P. ^{[6
]}

Latimer, Maya ^{[7
]}

Mackinlay, Naomi ^{[1
]}

Berkahn, Leanne ^{[8
]}

Simpson, David ^{[9
]}

Campbell, Philip ^{[10
]}

Forsyth, Cecily J. ^{[11
]}

Cull, Gavin ^{[12
]}

Harrup, Rosemary ^{[13
]}

Sulda, Melanie ^{[14
]}

Best, Giles ^{[15
]}

Bressel, Mathias ^{[16
]}

Di Iulio, Juliana ^{[16
]}

Kuss, Bryone J. ^{[14
,17
]}

机构：

[1] Royal N Shore Hosp, Sydney, NSW, Australia

[2] CLL Australian Res Consortium CLLARC, Sydney, NSW, Australia

[3] Australasian Leukaemia & Lymphoma Grp ALLG, Melbourne, Australia

[4] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia

[5] Austin Hosp, Melbourne, Vic 3084, Australia

[6] Royal Melbourne Hosp, Parkville, Vic 3050, Australia

[7] Canberra Hosp, Canberra, ACT, Australia

[8] Auckland Hosp, Auckland, New Zealand

[9] North Shore Hosp, Auckland, New Zealand

[10] Geelong Hosp, Andrew Love Canc Ctr, Geelong, Vic, Australia

[11] Gosford Hosp, Gosford, Australia

[12] Sir Charles Gairdner Hosp, Perth, WA, Australia

[13] Royal Hobart Hosp, Hobart, Tas, Australia

[14] Flinders Med Ctr, Adelaide, SA, Australia

[15] Univ Sydney, Kolling Inst, Sydney, NSW 2006, Australia

[16] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[17] Flinders Univ S Australia, Adelaide, SA 5001, Australia

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 42 条

[1] A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years - End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study
Mulligan, Stephen P.
Gill, Devinder S.
Turner, Paul
Renwick, William E. P.
Harrup, Rosemary
Latimer, Maya
Mackinlay, Naomi
Berkahn, Leanne
Simpson, David
Campbell, Philip
Tiley, Campbell
Cull, Gavin
Collins, Marnie
Cortissos, Paul
Sulda, Melanie
Best, Giles
Kuss, Bryone J.
BLOOD, 2012, 120 (21)
[2] TOXICITY AND RESPONSE BY COMORBIDITY AND AGE IN A RANDOMIZED STUDY OF ORAL FLUDARABINE AND CYCLOPHOSPHAMIDE WITH RITUXIMAB FIRST-LINE THERAPY OF FIT ELDERLY WITH CHRONIC LYMPHOCYTIC LEUKAEMIA
Mulligan, S.
Gill, D.
Turner, P.
Renwick, W.
Harrup, R.
Latimer, M.
Cull, G.
Berkahn, L.
Forsyth, C.
Mackinlay, N.
Simpson, D.
Campbell, P.
Tam, C.
Collins, M.
Sulda, M.
Best, G.
Kuss, B.
HAEMATOLOGICA, 2013, 98 : 42 - 42
[3] A RANDOMISED DE-ESCALATION STUDY OF ORAL FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN FIT ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: WELL TOLERATED AND SUPERIOR OUTCOMES WITH FCR
Mulligan, S.
Gill, D.
Renwick, W.
Turner, P.
Latimer, M.
Berkahn, L.
Simpson, D.
Campbell, P.
Forsyth, C.
Harrup, R.
MacKinlay, N.
Cull, G.
Kuss, B.
HAEMATOLOGICA, 2015, 100 : 53 - 53
[4] Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)
Mulligan, Stephen P.
Gill, Devinder
Turner, Paul
Renwick, William E. P.
Latimer, Maya
Mackinlay, Naomi
Berkahn, Leanne
Simpson, David R.
Campbell, Philip
Forsyth, Cecily J.
Cull, Gavin
Harrup, Rosemary
Sulda, Melanie
Best, Giles
Bressel, Mathias
Di Iulio, Juliana
Kuss, Bryone J.
BLOOD, 2014, 124 (21)
[5] FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE STUDY
Ionita, H.
Ionita, I.
Cheveresan, M.
Ionita, M.
Calamar, D.
Ionita, C. O.
Oros, D.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 526 - 526
[6] FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE ANALYSIS OF CZECH CLL STUDY GROUP
Smolej, L.
Lysak, D.
Papajik, T.
Salkova, J.
Brejcha, M.
Vozobulova, V.
Karban, J.
Hrudkova, M.
Cmunt, E.
Turcsanyi, P.
Jungova, A.
Krejcova, H.
Trneny, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 373 - 373
[7] The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years - Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study
Mulligan, Stephen P.
Gill, Devinder S.
Renwick, William E. P.
Sulda, Melanie L.
Best, O. Giles
Kuss, Bryone J.
Seymour, John F.
BLOOD, 2010, 116 (21) : 308 - 308
[8] Molecular and Genetic Characterization of Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As Initial Treatment of Chronic Lymphocytic Leukemia (CLL)
Badoux, Xavier C.
Best, Giles
Gabrielli, Sara
Hayes, Melanie
Zhu, Ying
Mulligan, Stephen
Kuss, Bryone J.
BLOOD, 2014, 124 (21)
[9] Fludarabine, cyclophosphamide and rituximab (FCR) first-line therapy in CLL patients: an analysis of the registry of the German CLL Study Group
Fink, A. M.
Federhen, A.
Kutsch, N.
Stumpf, J.
Giza, A.
Robrecht, S.
Stoltefuss, A.
Vehling-Kaiser, U.
Koenigsmann, M.
Tausch, E.
Schneider, C.
Stilgenbauer, S.
Illmer, T.
Schlag, R.
Doerfel, S.
Gaska, T.
Kiehl, M.
Fischer, K.
Eichhorst, B.
Hallek, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 119 - 120
[10] PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FLUDARABINE-CYCLOPHOSPHAMIDE REGIMEN IN THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS IN SPAIN
Bosch, F.
Casado, L. F.
Garcia-Marco, J. A.
Gilsanz, F.
Gonzalez Diaz, M.
Rayon, C.
Rios Herranz, E.
De la Serna, J.
Urbano, A.
Vicente Garcia, V.
Rubio-Terres, C.
Castro, A. J.
VALUE IN HEALTH, 2009, 12 (07) : A276 - A276

← 1 2 3 4 5 →